Your search for smoking cessation returned 282 results

According to a study in The American Journal of Drug and Alcohol Abuse, psilocybin showed promise in promoting long-term smoking abstinence in the context of a structured treatment program.

New trial data may alleviate some concerns regarding the smoking cessation medications varenline, bupropion and nicotine patches and the risk of neuropsych events.

Three years into the campaign, ads targeting smoking are still having a significant impact, according to the U.S. Centers for Disease Control and Prevention.

Stopping over time is less effective, British researchers say

Varenicline did not increase the rate of cardiovascular (CV) serious adverse events, according to data from a systematic review published in the Journal of the American Heart Association.

Researchers found no significant differences in rates of smoking abstinence at 26 or 52 weeks following a 12-week treatment with a nicotine patch, varenicline, or combination nicotine replacement therapy (nicotine patch + nicotine lozenge [C-NRT]), in adults trying to quit smoking.

Compared to those who continued smoking, those who stopped experienced a significant decline in the rate of brain volume loss.

According to a study in the journal Nicotine and Tobacco Research, the smoking cessation treatment varenicline is more effective for women in short and immediate outcomes compared to men, but is equally effective for both with longer outcomes.

Smoking cessation after acute myocardial infarction (AMI) reduces angina and boosts mental health and quality of life.

Smoking cessation may be associated with resurgence of anorexic symptoms in patients with a history of anorexia nervosa.